

- Sub
B1
Cont
- about 1 to 75% by weight uncrosslinked, linear water soluble polymers comprising a mixture of hydroxyethyl cellulose and hydroxypropyl methylcellulose;
 - up to about 10% by weight talc; and
 - up to about 10% by weight magnesium stearate.

B2

4. **(Amended)** The device of claim 1, wherein said polymers of acrylic acid crosslinked with polyalkenyl alcohols or divinyl alcohol are Carbopol resins.

Sub
B2

8. **(Amended)** The device of claim 1, wherein said device additionally comprises up to about 95% by weight granulating and tableting aids.

B4
Sub
B3

9. **(Amended)** A controlled release pharmaceutical delivery device which provides sustained or pulsatile delivery of a selected pharmaceutically active substance for a predetermined period of time, said device comprising;

- about 1 to less than 50% by weight of a mixture of hydroxyethylcellulose and hydroxypropylmethyl cellulose;
- about 1 to 60% by weight of ethylcellulose;
- about 1 to 80% by weight of at least one Carbopol® resin;
- up to about 10% by weight of talc;
- up to about 10% by weight of magnesium stearate; and
- up to about 95% by weight granulating and tableting aids.

Sub
B5

23. **(Amended)** A pharmaceutical composition comprising;

- about 1 to 80% by weight pharmaceutically active agent;
- up to about 50% by weight covalently crosslinked water insoluble, water-swellaable polymers comprising polymers of acrylic acid crosslinked with polyalkenyl alcohols or divinyl alcohol; and
- about 1 to 75% by weight uncrosslinked, linear water soluble polymers comprising a mixture of hydroxyethyl cellulose and hydroxypropyl methylcellulose.

B6
Sub
B5

30. **(Amended)** A pharmaceutical composition comprising;

- about 1 to 80% pharmaceutically active agent;

as
Ble
Cont

- about 1 to 60% by weight of hydroxyethylcellulose;
- about 1 to 75% by weight of hydroxypropylmethyl cellulose;
- about 1 to 60% by weight of ethylcellulose;
- up to about 50% by weight of at least one Carbopol® resin;
- about less than 10% by weight of talc;
- about less than 10% by weight of magnesium stearate; and
- about less than 95% by weight granulating and tableting aids.

Sub P7
C4

32. **(Amended)** A controlled release pharmaceutical delivery device which provides sustained or pulsatile delivery of a selected pharmaceutically active substance for a predetermined period of time, said device comprising;

- up to about 50% by weight covalently crosslinked water insoluble, water-swellaable polymers comprising polymers of acrylic acid crosslinked with polyalkenyl alcohols or divinyl alcohol;
- about 1 to 75% by weight uncrosslinked, linear water soluble polymers comprising a mixture of hydroxyethyl cellulose and hydroxypropyl methylcellulose; and
- about 0.5 to 50% by weight of a coating material comprising anionic polymers based on methacrylic acid and methacrylic acid esters or neutral methacrylic acid esters with trimethylammonioethyl methacrylate chloride or cellulose esters.

33. **(Amended)** A pharmaceutical composition comprising;

- about 1 to 80% by weight pharmaceutically active agent;
- up to about 50% by weight covalently crosslinked water insoluble, water-swellaable polymers comprising polymers of acrylic acid crosslinked with polyalkenyl alcohols or divinyl alcohol;
- about 1 to 75% by weight uncrosslinked, linear water soluble polymers comprising a mixture of hydroxyethyl cellulose and hydroxypropyl methylcellulose; and
- about 0.5 to 50% by weight of a coating material comprising anionic polymers based on methacrylic acid and methacrylic acid esters or neutral methacrylic acid esters with trimethylammonioethyl methacrylate chloride or cellulose esters.